MedTrace Logo

Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

NCT00225901 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2005-09-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether recombinant human hepatocyte growth factor is safe and effective in the treatment of fulminant and late-onset hepatic failure.

Conditions

  • Liver Failure, Acute

Interventions

DRUG

Recombinant human hepatocyte growth factor

Sponsors & Collaborators

  • Kyoto University, Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Tsutomu Chiba, M.D. · Kyoto University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225901 on ClinicalTrials.gov